

Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection

NCT07434063

Status	RECRUITING
Sponsor	Hebei Medical University Fourth Hospital
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (5)

- Patients with malignant tumors confirmed by histopathology or cytology; 2. Age ≥18 years old; 3. After referring to various guidelines, the researchers believed that the subjects:
- Patients who are currently receiving treatment regimens with high FN risk;
- Patients who are currently receiving treatment regimens for moderate FN risk and meet any one of the factors that increase the risk coefficient;
- FN or dose-limiting neutropenia events have occurred in previous treatment cycles;
- In addition to the above, the researchers believe that the medication regimens will cause neutropenia and affect the normal treatment of the subjects; 4. Researchers believe that they can benefit; 5. Voluntarily participate in this clinical trial and be able to sign the informed consent form in person.

Exclusion (1)

- Those who are allergic to the test drug 2. Those with mental or neurological disorders who are unable to cooperate 3. Pregnant or lactating female patients; Women of childbearing age who refuse to take contraceptive measures 4. Those who were considered unsuitable for inclusion by the researchers.

Locations (1 total)

HebeiMuFH, Shijiazhuang, Hebei, China